| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis (NCT07754786) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-10-20 |
| Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants (NCT07765160) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-08-30 |
| A Open-Label Phase in Participants With Multiple Myeloma (NCT07764861) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-08-15 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer (NCT07722494) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-07-31 |
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease (NCT07265258) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-07-30 |
| A Study of IBI3031 in Participants With Thyroid Eye Disease (NCT07622368) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-06-30 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 (NCT07623798) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-06-05 |
| Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT07612137) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-06-01 |
| Safety and Preliminary Activity of BI115 in Advanced SCLC (NCT07559019) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-05-21 |
| Study of IBI3016 in People With Mild or Moderate Hypertension Patients (NCT07556796) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-05-15 |
| A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis (NCT07549984) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-30 |
| A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers (NCT07502534) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-24 |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (NCT07469800) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-23 |
| Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration (NCT07554222) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-18 |
| IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07483567) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-17 |
| IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia (NCT07473960) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-04-01 |
| A Mutiple-dose Study of IBI3033 in Healthy Participants (NCT07456839) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-03-18 |
| A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis (NCT07399067) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-02-06 |
| A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients (NCT07352969) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-02-06 |
| IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer (NCT07402070) | Innovent Biologics (Suzhou) Co. Ltd. | 2026-02-04 |
| A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants (NCT07311226) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-12-31 |
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (NCT07330934) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-12-31 |
| A Study of IBI362 in Chinese Adolescents With Obesity or Overweight (NCT07255209) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-12-29 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011 (NCT07295496) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-12-08 |
| Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression (NCT07199010) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-10-01 |
| A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease (NCT07113262) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-09-10 |
| A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors (NCT07124793) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-08-31 |
| IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer (NCT07122687) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-08-26 |
| A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) (NCT07066098) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-08-04 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (NCT06937749) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-07-01 |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity (NCT07000955) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-06-17 |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 (NCT06931028) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-06-12 |
| Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases (NCT07008287) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-06-04 |
| A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants (NCT06947408) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-05-14 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） (NCT06884293) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-05-09 |
| IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT06974812) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-04-18 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity (NCT06862908) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-04-01 |
| Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT06834672) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-03-17 |
| A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy (NCT06797297) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-02-24 |
| IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT06349408) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-01-10 |
| Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT06418061) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-01-08 |
| A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease (NCT06525506) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-09-04 |
| This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity (NCT06536023) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-08-30 |
| A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT06198426) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-08-19 |
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (NCT06083207) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-07-29 |
| Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome (NCT06484855) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-07-14 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects (NCT06501534) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-07-10 |
| A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) (NCT06238843) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-06-30 |
| A Study of IBI363 in Subjects With Advanced Malignancies (NCT06468098) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-06-15 |
| Safety and Tolerability of IBI355 in Healthy Volunteers (NCT06416787) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-05-20 |
| A Study of IBI363 in Subjects with Advanced Solid Malignancies (NCT06281678) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-04-08 |
| Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer (NCT05116462) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-03-15 |
| A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT05991349) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-03-12 |
| A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (NCT06277752) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-03-05 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity (NCT06184568) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-02-29 |
| A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics (NCT06213844) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-02-26 |
| A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours (NCT06170190) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-01-16 |
| A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (NCT06193434) | Innovent Biologics (Suzhou) Co. Ltd. | 2024-01-05 |
| A Study of IBI362 9 mg in Chinese Adults With Obesity (NCT06164873) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-12-27 |
| A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (NCT05923008) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-11-14 |
| Safety and Tolerance Study of IBI355 in Health Volunteers (NCT06110338) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-10-30 |
| A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease (NCT06126783) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-10-20 |
| A Study of IBI363 in Subjects With Advanced Melanoma (NCT06081920) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-10-19 |
| IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment (NCT06049810) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-10-10 |
| A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD (NCT05972473) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-09-21 |
| A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics (NCT05970978) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-08-28 |
| The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. (NCT05774873) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-08-09 |
| The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) (NCT05849246) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-07-31 |
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer (NCT05890742) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-05-25 |
| Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment (NCT05793450) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-05-05 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects (NCT05815680) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-04-06 |
| A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05636215) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-04-04 |
| IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer (NCT05653180) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-03-10 |
| A Study of IBI351 in Healthy Subjects (NCT05699993) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-03-10 |
| Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers (NCT05792917) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-03-06 |
| A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (NCT05639530) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-27 |
| A Study of [14C]IBI351 in Healthy Subjects (NCT05626179) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-18 |
| A Study of IBI351 in Healthy Subjects (NCT05688124) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-16 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease (NCT05795621) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-14 |
| A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis (NCT05645627) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-02-10 |
| A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise (NCT05628311) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-01-06 |
| A Study of IBI353 (Orismilast) in Chinese Healthy Adults (NCT05490316) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-11-30 |
| A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma (NCT05572463) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-11-01 |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05458219) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-10-26 |
| Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (NCT05504278) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-09-20 |
| Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma (NCT05460767) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-08-31 |
| A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas (NCT05290597) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-08-22 |
| A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer (NCT05497336) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-08-18 |
| A Study of IBI311 in Healthy Volunteers (NCT05480579) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-08-10 |
| A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema (NCT05489718) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-08-01 |
| A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis (NCT05377580) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-07-01 |
| A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (NCT05403749) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-06-29 |
| IBI397 or Combination Therapies in Patients With Advanced Malignancies (NCT05245916) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-04-14 |
| Phase I Study of Sintilimab in Healthy Chinese Male Subjects (NCT05337267) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-04-13 |
| First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP (NCT05280626) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-25 |
| Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (NCT05164458) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-22 |
| A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (NCT05172856) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-01 |
| A Phase I Study of IBI325 in Patients With Advanced Solid Tumor (NCT05119998) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-02-08 |
| A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 (NCT05162365) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-01-06 |
| A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19 (NCT05172141) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-12-31 |